Alzheon, a clinical-stage biopharmaceutical company based in Framingham, MA, has raised $100 million in Series E funding.
The funding round was led by Alerce Medical Technology Partners. Alzheon, which secured $50 million in a Series D round in 2022, plans to use the new funds to expand its operations and research and development sector.
Founded by Martin Tolar, MD, PhD, who serves as President and CEO, Alzheon is dedicated to developing a wide range of product candidates and diagnostic assays for patients with Alzheimer’s disease and other neurodegenerative disorders. The company focuses on innovative medicines that directly address the underlying pathology of neurodegeneration. Alzheon’s lead Alzheimer’s clinical candidate, ALZ-801 (valiltramiprosate), is an oral agent in Phase 3 development aimed at potentially modifying the course of the disease. Preclinical tests have shown that ALZ-801 can fully block the formation of neurotoxic soluble amyloid oligomers. Alzheon’s clinical expertise and technology platform utilize a precision medicine approach, leveraging individual genetic and biomarker information to develop impactful therapies for patients.
